Abstract Number: PB1906
Meeting: ISTH 2020 Congress
Background: antiphospholipid antibodies (aPLa) have a multifaceted effect on the hemostatic system, damaging its entire protective links: the endothelial barrier, the function of natural anticoagulants, endogenous fibrinolysis, activating the platelet link of hemostasis and are associated with many obstetric complications and infertility. But there is little data about the frequency of aPLa circulation in women with in vitro fertilization (IVF) failures and is aPLa associated with a worse reproductive outcome?
Aims: To evaluate the frequency of aPLa in women undergoing assisted reproductive technologies (ART).
Methods: 267 women aged 23 to 45 years who were in the IVF program were examined. Of these, 178 women had IVF failures (one or more failed IVF attempts, the number of attempts ranged from 1 to 9) (group I) and 89 women with pregnancy after the IVF program (group II).
Results: aPLa circulation was diagnosed in 42.1% of patients of the group I. Attention is drawn to the high percentage of antibodies to β2-GPI-31.4% and to annexin V-24.7%. aPLA circulation was also detected in the group II in 19.1%. At the same time, lower aPLA titers were observed compared to group I (see table 1). All women received aspirin low doses before starting IVF procedure and LMWH during protocol.
Conclusions: women with aPLA circulation demonstrate a higher rate of IVF failure and a worse reproductive outcome compared to women without aPLA. We believe that the circulation of aPLA is a temporary contraindication to ART and attribute the successful onset of pregnancy in group II, despite the presence of antiphospholipid antibodies, to the timely initiation of therapy. We consider that it is necessary to examine women who are planning a pregnancy using IVF for the presence of aPLA, as well as the need to start anticoagulant therapy before IVF protocol.
|aPLA profile||Women with IVF failure (I group), n=178, % (n)||Pregnancy after IVF (II group), n=89, % (n)||Control group, N=80, %(n)|
|APA (total)||42.1 (75)||19.1 (17)||3.4 (3)|
|Antibodies to cardiolipin (IgG/M)||8.9 (16)||3.4 (3)||1.3 (1)|
|LA circulation||19.6 (35)||4.5 (4)||1.3 (1)|
|Antibodies to annexin V (IgG/M)||24.7 (44)||10.1 (9)||0|
|Antibodies to b2GPI (IgG/M/A)||31.4 (56)||14.6 (13)||3.8 (3)|
|Antibodies to prothrombin (IgG/M/A)||13.5 (24)||7.9 (7)||0|
[aPLA profile in women undergoing IVF program]
To cite this abstract in AMA style:Khizroeva J, Makatsariya A, Bitsadze V, Arslanbekova M, Sultangadzhieva K. IVF Outcomes in Women with Antiphospholipid Antibodies Circulation [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/ivf-outcomes-in-women-with-antiphospholipid-antibodies-circulation/. Accessed January 23, 2022.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/ivf-outcomes-in-women-with-antiphospholipid-antibodies-circulation/